Valuation: Bicycle Therapeutics plc

Market Cap 248M 222M 205M 186M 348M 23.59B 353M 2.47B 977M 12.36B 933M 913M 38.96B P/E 2026 *
-1.36x
P/E 2027 * -1.52x
Enterprise Value -264M -236M -218M -198M -370M -25.09B -376M -2.62B -1.04B -13.15B -992M -971M -41.45B EV / Sales 2026 *
-15.1x
EV / Sales 2027 * -23.2x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day-2.47%
1 week+2.60%
Current month-3.53%
1 month-1.39%
3 months-14.66%
6 months-26.80%
Current year-49.86%
1 week 3.41
Extreme 3.41
3.8
1 month 3.33
Extreme 3.3301
4.04
Current year 3.33
Extreme 3.3301
7.34
1 year 3.33
Extreme 3.3301
9.08
3 years 3.33
Extreme 3.3301
28.67
5 years 3.33
Extreme 3.3301
62.08
10 years 3.33
Extreme 3.3301
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Sell

Chief Operating Officer

-356 0.0009%
5/10/26 Sell

Chief Operating Officer

-406 0.0011%
5/10/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-2.47%+2.60%-54.55%-77.43% 248M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.00%+2.43%+39.10%+134.05% 38.34B
Weighted average by Cap. +0.39%+2.73%+47.51%+158.42%

Financials

2026 *2027 *
Net sales 17.53M 15.66M 14.46M 13.11M 24.52M 1.66B 24.93M 174M 68.91M 872M 65.8M 64.4M 2.75B 6.69M 5.97M 5.52M 5M 9.36M 635M 9.51M 66.4M 26.29M 333M 25.1M 24.57M 1.05B
Net income -172M -154M -142M -129M -241M -16.33B -245M -1.71B -676M -8.56B -646M -632M -26.98B -174M -156M -144M -130M -244M -16.56B -248M -1.73B -685M -8.67B -655M -641M -27.35B
Net Debt -513M -458M -423M -383M -717M -48.68B -729M -5.09B -2.02B -25.51B -1.92B -1.88B -80.41B -403M -360M -333M -302M -564M -38.29B -573M -4B -1.59B -20.06B -1.51B -1.48B -63.25B
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
23/10/26 US$3.550 -2.47% 346,808
22/10/26 US$3.640 +1.96% 276,237
21/10/26 US$3.570 -0.83% 406,403
20/10/26 US$3.600 +1.84% 488,210
19/10/26 US$3.535 +2.17% 692,062
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.550USD
Average target price
9.500USD
Spread / Average Target
+167.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bicycle Therapeutics plc
  1. Stock Market
  2. Stocks
  3. BCYC Stock